Skip to main content
. 2019 Apr 30;11:3741–3751. doi: 10.2147/CMAR.S189558

Figure 3.

Figure 3

CLDN8 enhances the MAPK/ERK signaling pathway in CRC cells.

Notes: (A–C) The expression of MMP9 was significantly upregulated in CLDN8 overexpression group. In addition, CLDN8 overexpression significantly enhanced the levels of p-ERK, whereas CLDN8 knockdown reduced their expression level. (D–F) CLDN8 overexpression remarkably inhibited the protein expression level of E-cadherin, whereas CLDN8 knockdown effectively upregulated its expression. In contrast, the expression level of N-cadherin was upregulated under CLDN8 overexpression, but downregulated under CLDN8 knockdown. (G–I) Treatment of CLDN8-overexpressed SW480 and HT-29 cells with PD98059 significantly impaired CLDN8-induced ERK phosphorylation. *P<0.05 when compared with CLDN8-NC. (J–L) Application of PD98059 significantly impaired CLDN8-induced E-cadherin inhibition and N-cadherin enhancement, respectively. (M, N) Enhanced invasion of CRC cells in response to CLDN8 overexpression was reduced after the application of PD98059. *P<0.05 when compared with CLDN8; #P<0.05 when compared with CLDN8-NC. CLDN8-NC, the negative control group of CLDN8 overexpression. Bar = 100μm.

Abbreviation: CRC, colorectal cancer.